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BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC), a matricellular glycoprotein, modulates cellular interaction with
the extracellular matrix and is capable of altering the growth of various cancers. We therefore sought to determine the effect of
SPARC expression on medulloblastoma tumour growth and angiogenesis.
METHODS: To this extent, we selected three SPARC full-length cDNA overexpressed clones (Daoy-SP). Consequences of SPARC
overexpression were studied in terms of cell growth, angiogenesis using co-culture assay in vitro, dorsal skin-fold chamber assay in vivo,
PCR Array for human angiogenic genes, as well as western blotting for angiogenic molecules and tumour growth, in an orthotopic
tumour model.
RESULTS: The SPARC protein and mRNA levels were increased by approximately three-fold in Daoy-SP cells compared with parental
(Daoy-P) and vector (Daoy-EV) controls. Daoy-SP clones reduced tumour cell-induced angiogenesis in vitro and in vivo, and formed
small tumours with fewer blood vessels when compared with controls. Matrix metalloprotease-9 (MMP-9) and vascular endothelial
growth factor (VEGF) expression were decreased in Daoy-SP clones. Further, inhibition of MMP-9 expression caused SPARC-
mediated inhibition of angiogenesis and tumour growth as MMP-9 rescued SPARC-mediated anti-angiogenic effect in vitro and
tumour growth inhibition in vivo.
CONCLUSION: Overexpression of SPARC decreases angiogenesis, which leads to decreased tumour growth. Further, the role of
MMP-9 could be attributed to the anti-angiogenic effect of SPARC.
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Medulloblastoma (MB) is a malignant embryonal tumour that is
predominantly diagnosed in children and continues to pose a
difficult clinical management problem. Medulloblastomas occur
principally in the midline cerebellar region but are prone to invade
the meninges and cerebrospinal fluid spaces. With aggressive
surgery, craniospinal radiotherapy and chemotherapy, only
slightly 450% of children diagnosed with medulloblastoma are
disease free after 5 years (Eberhart et al, 2002; Guerreiro et al,
2008; Packer and Vezina, 2008). Furthermore, current treatment
for medulloblastoma carries a high risk of long-term morbidity,
with the majority of patients having some degree of hormonal,
auditory and neurocognitive impairment (Ris et al, 2001). Even
with conventional chemotherapy and radiotherapy, only a subset
of patients are cured; thus, a great need for new therapeutic
approaches exists (Packer, 1999; Zeltzer et al, 1999). Similar to
many other central nervous tumours, some PNET/MB tumours
show marked neovascularisation (Assimakopoulou et al, 1997).
Medulloblastomas produce a wide range of angiogenic factors that
are, either individually or together, likely to have a direct role in
tumour growth, tumour progression and angiogenesis (Pavlakovic
et al, 2001a). Previous reports indicate that assessment of
angiogenesis by microvessel density and quantification is
significantly higher in medulloblastomas associated with poor
prognosis (Ozer et al, 2004).
Secreted protein acidic and rich in cysteine (SPARC/
osteonectin/BM-40) is a secreted macromolecule that interacts
with cell-surface receptors, the extracellular matrix (ECM) and/or
growth factors and proteases (Bornstein and Sage, 2002). The role
of SPARC in tumourigenesis is complex and seems to be cell-type
specific owing to its diverse functions in a given micro-
environment. Solid tumours in SPARC-null mice grew significantly
larger than those in wild-type animals (Brekken et al, 2003). The
SPARC functions as a tumour suppressor in neuroblastoma,
breast, pancreatic, lung and ovarian cancers (Framson and Sage,
2004). In addition, SPARC modulates angiogenesis and regulates
the production, assembly and organisation of the ECM (Sage et al,
1984; Bradshaw and Sage, 2001). By directly binding to vascular
endothelial growth factor (VEGF), SPARC inhibits microvascular
endothelial cell proliferation stimulated by VEGF165, indicating
that it has anti-angiogenic activity (Yan and Sage, 1999; Chlenski
et al, 2006; Chandrasekaran et al, 2007). The SPARC binds to
VEGF, thus inhibiting VEGF interaction with endothelial cell
surface, VEGFR1 autophosphorylation, ERK1/2 activation and
VEGF-induced DNA synthesis (Kupprion et al, 1998). The SPARC
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PDGF-BB on endothelial cells and inhibits the interaction of these
growth factors with their tyrosine kinase receptors (Raines et al,
1992). In addition, SPARC influences the levels and activity
of several angiogenic molecules (e.g., PDGF, fibroblast growth
factor-2 (FGF-2), VEGF and insulin-like growth factor) (Francki
et al, 1999, 2003; Brekken and Sage, 2001). Further, SPARC can
inhibit angiogenesis indirectly by regulating the expression of
other angiogenesis-related genes, such as matrix metalloproteases
(MMPs) (Shankavaram et al, 1997) and transforming growth
factor-b 1 (Francki et al, 1999). However, its role in tumour-
induced angiogenesis seems to be tumour specific. Recent studies
demonstrate that overexpression of SPARC led to a significant
decline in microvessel density, resulting in delayed tumour
formation and reduction in tumour size in hepatocellular
carcinoma xenografts (Lau et al, 2006). The SPARC blocks
angiogenesis in vitro and in vivo in neuroblastoma and is one of
the key contributors to the anti-angiogenesis activity of the
Schwann cell-conditioned medium (Chlenski et al, 2002).
However, other studies point to the pro-angiogenic activity of
SPARC. For example, SPARC was found high levels in breast
cancer, colon cancer (Bellahcene and Castronovo, 1995; Porte et al,
1995), metastatic melanoma (Ledda et al, 1997) and invasive
meningioma (Rempel et al, 1999).
In this study, we examined the effects of SPARC on
medulloblastoma tumours in vitro and in vivo and whether
inhibition of angiogenesis is implicated in the anti-tumour effect of
SPARC. To elucidate the role of SPARC, we enhanced SPARC
expression in medulloblastoma cells using stable transfection and
expression constructs with SPARC full-length cDNA driven by a
CMV promoter. We developed three human medulloblastoma cell
lines designated as Daoy-SP1/2/3, which stably express human
SPARC cDNA. The SPARC expression reduced xenograft growth
with reduced vascularity in an orthotopic medulloblastoma
model. We also demonstrated that SPARC expression inhibits
VEGF-mediated angiogenesis by altering MMP-9 expression,
thereby leading to reduced angiogenesis.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies against SPARC, VEGF, epidermal growth factor
receptor, fibroblast growth factor receptor (FGFR), PDGFR,
VEGFR2, CD31, MMP-9 and major histocompatibility complex
(MHC) class-I (Santa Cruz Biotechnology, Santa Cruz, CA, USA);
Von-Willebrand factor (Factor-VIII) (DAKO Corp., Carpinteria,
CA, USA); and MHC class-I antibody for immunohistochemistry
(Serotec, Inc., Raleigh, NC, USA) were used. The RT
2 PCR Array
for angiogenesis (SA Biosciences, Frederick, MD, USA) was also
used in this study. All other reagents were of analytical grade or
better.
Daoy cell culture
Daoy cells were obtained from ATCC (Manassas, VA, USA) and
cultured in Advanced-MEM supplemented with 5% foetal bovine
serum, 2mMl
–1 L-glutamine, 100unitsml
–1 of each penicillin and
100mgml
–1 streptomycin. Cells were maintained in a humidified
atmosphere containing 5% CO2 at 371C.
Construction of pcDNA3.1-SPARC and transfection of
Daoy cells
An 1100-bp cDNA fragment of human SPARC was amplified by
PCR using synthetic primers and sub-cloned into a pcDNA3.1
vector (Invitrogen, San Diego, CA, USA) in sense orientation. Daoy
cells were transfected with full-length cDNA of SPARC containing
vector or empty vector using FuGene HD (Roche, Indianapolis,
IN, USA) as described earlier (Mohanam et al, 2001). Stable
transfectants were selected with cloning cylinders after 3–4 weeks
in medium containing G418. Wild-type Daoy cells are termed as
Daoy parental (Daoy-P) and the stable cell lines overexpressing
SPARC were designated as Daoy-SP, whereas Daoy-EV was the cell
line transfected stably with the empty vector.
Immunofluorescence microscopy
We used a previously described protocol with minor changes
(Chetty et al, 2007). Briefly, cells were cultured on eight-well
chamber slides and fixed with 4% (w/v) paraformaldehyde in
phosphate-buffered saline (PBS), permeabilised with 0.1% (w/v)
Triton X-100 in PBS and blocked with 1% (w/v) bovine serum
albumin in PBS for 1h at 41C. Cells were incubated overnight
either with anti-SPARC or with anti-Von-Willebrand factor
antibody (1:100 dilution) at 41C, followed by the corresponding
Texas Red/fluorescent isothiocyanate (1:200 dilution)-conjugated
secondary antibody for 1h, and mounted with mounting medium
containing 4,6-diamidino-2-phenylindole. The results were docu-
mented using a fluorescence microscope.
Western blotting
Western blot analysis was performed as described previously
(Bhoopathi et al, 2008). Briefly, 36h after seeding, Daoy-P,
Daoy-EV and Daoy-SP cells were collected and lysed in RIPA
buffer. Equal amounts of proteins were resolved on SDS–
polyacrylamide gel electrophoresis and transferred onto a PVDF
membrane. The blot was blocked with 5% non-fat dry milk and
probed overnight with primary antibodies (1:1000 dilution),
followed by horseradish peroxidase-conjugated secondary anti-
bodies (1:2500 dilution). An ECL system was used to detect
chemiluminescent signals. All blots were re-probed with GAPDH
antibody to confirm equal loading.
siRNA design and transient transfection
The SPARC small interfering RNA (siRNA) sequences were
designed with the help of a siRNA designer programme (Imgenex,
Sorrento Valley, CA, USA). The siRNA was complementary to an
exonic sequence of the target mRNA and compatible with the
pcDNA3.1 vector (Invitrogen, San Diego, CA, USA). The following
siRNA sequence 50- TCGAGGGTGTGCAGCAATGACAACAAGA
GTCGTCGTTGTTGTCATTGCTGCACACCG-30 was used to con-
struct SPARC siRNA. A control vector containing siRNA with
a scrambled sequence was constructed and designated as pSV.
We used the following scrambled sequence: 50-CACGGAGGTTG
CAAAGAATAATCGATTATTCTTTGCAACCTCCGTGC-30. FuGene
HD transfection reagent (Roche; 1mg plasmid: 3ml of FuGene HD)
was used for transfections as per the manufacturer’s instructions.
After transfection, the cells were cultured in Advanced-MEM with
5% foetal bovine serum for 24h, rinsed once with PBS and cultured
for an additional 16h in serum-free Dulbecco’s modified Eagle’s
medium/F12 50/50. Conditioned medium and cell lysates were
collected, and MMP-9 and SPARC levels were determined by
gelatin zymography and western blot analysis, respectively.
Reverse transcriptase PCR
Daoy-P, Daoy-EV and Daoy-SP cells were grown for 36h. Total
RNA was extracted from these cells and cDNA was synthesised
using poly-dT primers as described earlier (Chetty et al, 2008).
PCR was performed using the following primers: SPARC,
50-GGAAGAAACTGTGGCAGAGG-30 (sense) and 50-ATTGCTGC
ACACCTTCTCAA-30 (antisense); GAPDH, 50-TGAAGGTCGGAG
TCAACGGATTTGGT-30 (sense) and 50-CATGTGGGCCATGAGG
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was carried out by densitometry.
Cell proliferation assays
Cell proliferation was determined using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (R&D
Systems, Minneapolis, MN, USA) as previously described (Rao
et al, 2007). Briefly, Daoy-P, Daoy-EV and Daoy-SP (SP1, SP2 and
SP3) cells (5000cells per well) were seeded in 96-well cell culture
plates and incubated up to 60h. After 0–60h, MTT reagent was
added, incubated for 4h at 371C and the absorbance of formazan
was measured with a microplate reader at A550.
In vitro angiogenesis assay
Tumour cell-induced microtubule network formation was deter-
mined as described previously (Gondi et al, 2004). Daoy-P,
Daoy-EV and Daoy-SP cells (2 10
4 per well), either with SPARC
siRNA, anti-SPARC antibody treatment or alone, were seeded in
eight-well chamber slides and allowed to grow for 24h. Thereafter,
the medium was removed and HMEC cells (4 10
4cells per well)
were added. After 36h of co-culture, cells were stained with factor-
VIII antigen. The formation of tubular capillary-like structures,
which is an indicator of angiogenesis, was assessed by confocal
microscopy. Image Pro Discovery software (Media Cybernetics,
Inc., Bethesda, MD, USA) was used to quantify the tube length.
Dorsal skin-fold chamber model
In vivo angiogenesis assay was performed as described previously
(Lakka et al, 2005). Briefly, Daoy-P, Daoy-EV and Daoy-SP cells
(1 10
6 cells in 100ml) were injected into diffusion chambers
(Fisher, Pittsburg, PA, USA) and sealed with bone wax. Athymic
nude female mice (4–6 weeks old; five per group) were
anaesthetised with ketamine:xylazine (100:10mgkg
–1). A dorsal
air sac was created by subcutaneously injecting 5ml of air, and a
superficial incision was made at the edge of the air sac through
which the chambers were placed underneath the skin. After 10
days, the animals were killed and the skin area covering the
chambers was removed and photographed. The number of tumour
cell-induced blood vessels was counted in five different fields as
described previously (Lakka et al, 2005).
RT
2 profiler PCR array
Total RNA was isolated from Daoy-P, Daoy-EV and Daoy-SP cells
and cDNA was synthesised as described above. The human
angiogenesis signalling pathway RT
2 Profiler PCR Array was used
to profile the expression of 84 genes related to the angiogenesis
signalling pathway, according to manufacturer’s instructions. The
fold change of mRNA expression was calculated on the basis of the
cycle threshold (Ct) values obtained from the real-time PCR
experiment. The scatter plot of test vs control samples indicated
the validity of the experiment.
Intracranial tumour model and immunohistochemistry
All animal experiments were carried out after obtaining approval
from the Institutional Animal Care and Use Committee on a
project-specific basis in accordance with the Public Health Service
Policy on Humane Care and Use of Laboratory Animals (PHS
Policy), and meet the standards required by the UKCCCR
guidelines (Workman et al, 1988). Animals were housed in
pathogen-free conditions in a light/dark cycle of 12/12h and fed
with rodent chow and water ad libitum. Daoy cells with or without
treatments (1 10
5cells, six animals per group, Daoy-P, Daoy-EV,
Daoy-SP2, Daoy-EVþpcMMP9 and Daoy-SP2þpcMMP-9 cells)
were stereotactically implanted as described previously (Bhoopathi
et al, 2008). Animals were monitored for 180 days, which was the
designated termination point of the experiment. Animals who lost
420% of body weight or had trouble ambulating, feeding or
grooming were killed. For histological analysis, brains were snap
frozen and maintained at  701C until sectioning. Tumour volume
was assessed as described previously (Ding et al, 2005). Briefly, all
brains were serially sectioned, and 8-mm sections were incubated
with mAb anti-human-specific MHC class-I IgG (10mgml
–1, 2h, at
41C; mAb W6/32, Serotec, Inc.), followed by a multi-link secondary
antibody conjugated to biotin and horseradish peroxidase,
followed by incubation with streptavidin, and then 3,30-diamino-
benzidine substrate (Sigma, St Louis, MO, USA). Digital images
were imported into Adobe Photoshop (San Jose, CA, USA), stained
areas in each section were quantified as a pixel number and pixel
numbers for all sections from each brain were summed to obtain a
total pixel number. Excised brains were fixed in 10% buffered
formalin and embedded in paraffin. Tissue sections (5mm thick)
were obtained from the paraffin blocks and were stained with
haematoxylin and eosin using standard histological techniques.
For immunohistochemical analysis, sections were incubated with
mAb (1h, RT), followed by the appropriate secondary antibody.
For horseradish peroxidase-conjugated secondary antibody
incubation, we used 3,30-diaminobenzidine solution as chromogen.
Nucleus was counterstained with either haematoxylin or
4,6-diamidino-2-phenylindole. Negative control slides were ob-
tained by nonspecific IgG. Sections were mounted with mounting
solution and analysed using an inverted microscope.
Statistical analysis
All data are expressed as mean±s.e. Statistical analysis was
performed using Student’s t-test or a one-way analysis of variance.
A P-value of o0.05 was considered statistically significant. All
experiments were performed in triplicate with consistent results.
RESULTS
Overexpression of SPARC in Daoy cells
The SPARC, a prototype of the matricellular protein family, was
shown to have an important role in various aspects of
tumourigenesis, including tumour invasion, angiogenesis and
tumour growth. To experiment with a genetic approach to induce
SPARC expression and observe its effects on medulloblastoma
tumour growth in vitro and in vivo, we cloned a human SPARC
cDNA in a pcDNA3.1 mammalian expression vector and
transfected it into Daoy parental (Daoy-P) cells. The stable cell
lines overexpressing SPARC were designated as Daoy-SP, whereas
the stable cell line expressing the empty vector (pcDNA3.1) was
designated as Daoy-EV. We randomly tested clones for mRNA
expression of SPARC transcript (data not shown) and selected
three SPARC-overexpressed stable clones. Figure 1A indicates that
SPARC transcript levels were increased in the three clones tested
when compared with parental and vector controls. There was
about a three-fold increase in mRNA transcript levels in Daoy-SP
clones (Daoy-SP1, Daoy-SP2 and Daoy-SP3; Po0.01 vs controls;
Figure 1B). To confirm that this upregulation of SPARC mRNA
translated into increased levels of SPARC protein, we next
performed western blot and immunocytochemical analyses for
SPARC expression in these three Daoy-SP clones. We found a
three- to four-fold increase in SPARC expression in Daoy-SP
clones compared with parental and empty vector controls
(Po0.01; Figure 1B). As assessed by immunofluorescence micro-
scopy, the distribution of SPARC indicated intense staining in all
three Daoy-SP clones, compared with Daoy-P and Daoy-EV
controls (Figure 1C).
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To determine whether SPARC overexpression affected the growth
of Daoy cells, the growth rates of SPARC-overexpressed cells were
compared with those of parental and empty vector controls. A very
minimal decrease in proliferation was observed at 24h (5–8%).
At 48h, there was an B15% decrease in proliferation in all three
SPARC-overexpressed clones, compared with Daoy-P and
Daoy-EV cells. Finally, at 60h, there was a 24, 30 and 25%
inhibition of Daoy-SP1, Daoy-SP2 and Daoy-SP3 cells, respectively,
compared with Daoy-P and Daoy-EV cells (Figure 1D).
SPARC decreases tumour-induced angiogenesis in vitro
and in vivo
Previous studies indicate that purified SPARC blocked endothelial
cell migration in a dose-dependent manner in PNET tumours
(Chlenski et al, 2002). To confirm this effect in SPARC-overexpressed
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Figure 1 Overexpression of secreted protein acidic and rich in cysteine (SPARC) in Daoy medulloblastoma cells inhibits Daoy cell proliferation. Daoy
cells were stably transfected with plasmid containing full-length SPARC cDNA and empty vector. (A) Total RNA was extracted using Trizol reagent, and
reverse transcriptase PCR was performed for assessment of SPARC mRNA transcript level. GAPDH served as a control for RNA quality. SPARC protein
levels were determined in total cell lysates by western blot analysis using SPARC-specific antibody. GAPDH was used to confirm equal loading of cell lysates.
(B) Protein and mRNA transcripts level were quantified by densitometric analysis as shown in the corresponding bar graph. Columns, mean of triplicate
experiments; bars, s.e.; *Po0.01, significant difference from Daoy-P control cells. (C) Immunocytochemical analysis for SPARC in different
SPARC-overexpressed clones. Mouse IgG was used as negative control. (D) Daoy-P, Daoy-EV and Daoy-SP cells (5000cells) were plated in 96 well
plates, incubated for 0–60h and 20ml of 0.5mgml
–13-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) in phosphate-buffered saline
(PBS) were added to cells. The cells were incubated for another 4h. Next, the medium was removed from each well and dimethyl sulphoxide (DMSO)
(100ml) was added to each well to dissolve the formazan crystals. Absorbance values at 550nm were measured with a microplate reader and the results
were presented with the comparison of cells treated with vehicle. Points, mean of triplicate experiments; bars, s.e.
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endothelial cells in an in vitro angiogenic assay as described in the
‘Materials and methods’ section; cell number was corrected for 5–8%
inhibition at the 24h time point in cell growth in Daoy-SP clones as
compared with controls. Daoy-P and Daoy-EV cells cultured with
endothelial cells elicited a strong angiogenic response and induced
HMECs to differentiate into capillary-like structures within 36h.
In contrast, microvessel morphogenesis was impeded in the co-
cultures of HMECs and Daoy-SP clones. Quantification indicated a
75–80% decrease in the formation of branch points and a 60–75%
decrease in vessel length in HMEC cells cultured with Daoy-SP
c l o n e s ,c o m p a r e dw i t hH M E Cc e l l sc u l t u r e dw i t hD a o y - Pa n d
Daoy-EV (Figure 2A).
We also examined whether Daoy-SP clones could inhibit tumour
angiogenesis in vivo as assessed by the dorsal window model.
Implantation of a chamber containing Daoy-P and Daoy-EV cells
in the dorsal skin-fold chamber resulted in the development of
tumour-induced microvessels (TN) with curved thin structures
and many tiny bleeding spots. In contrast, implantation of
Daoy-SP cells (cell number corrected for growth inhibition) had
a 50–75% decrease in tumour-induced microvessels, compared
with Daoy-P and Daoy-EV cells (Figures 2B and C).
To further test the effect of increased expression of SPARC on
angiogenesis in vitro, we inhibited SPARC expression using siRNA
or antibody against SPARC in Daoy-SP cells and tested their ability
to induce endothelial cell network formation. Figure 2D indicates
that SPARC expression in SPARC siRNA-transfected Daoy-SP cells
was decreased compared with that in Daoy-SP cells and was
comparable with that of Daoy-P parental controls. However, as
shown in Figure 2A, siRNA against SPARC or anti-SPARC
antibody could not restore Daoy-SP tumour cell-induced angio-
genesis. Taken together, these data suggest that the decreased
angiogenesis in SPARC-overexpressed cells could be because of
SPARC-induced altered cellular composition rather than the effect
of SPARC expression itself.
Overexpression of SPARC modulates angiogenic factors
To better determine the mechanisms underlying SPARC-mediated
inhibition of angiogenesis, we used the human angiogenesis
signalling pathway RT
2 Profiler PCR Array to profile the
expression of 84 genes related to the angiogenesis signalling
pathway. Total RNA from Daoy-P, Daoy-EV and Daoy-SP2 cells
(Daoy-SP2 cells exhibited higher anti-angiogenic effect than
Daoy-SP1 and Daoy-SP3) was used to synthesise cDNA. Real-time
PCR was performed as per the manufacturer’s instructions and
fold change of mRNA expression was calculated on the basis of
Ct values. The scatter plot of the test (Daoy-SP2) vs control
(Daoy-EV) samples indicates the validity of the experiment
(Figure 3A). It is evident from the results that SPARC over-
expression led to decreased expression of pro-angiogenic factors
(e.g., VEGF, FGFR, ECGF and MMP-9), as well as increased
expression of anti-angiogenic factors (e.g., TIMP-3 and transform-
ing growth factor-b; Figure 3B). To confirm the PCR array results,
protein levels of pro-angiogenic molecules in cell lysates from
Daoy-P, Daoy-EV and Daoy-SP2 cells were assessed using western
blotting (Figure 3C). When adjusted for parental controls,
densitometry analysis revealed a 65, 78 and 70% decrease in
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Figure 2 Overexpression of secreted protein acidic and rich in cysteine (SPARC) in Daoy cells inhibits tumour-induced angiogenesis in vitro and in vivo.
(A) In vitro angiogenesis: Daoy-P, Daoy-EV and Daoy-SP cells (2 10
4 per well), either with SPARC siRNA treatment or with anti-SPARC antibody
treatment, were seeded in eight-well chamber slides. After 24h, the medium was removed and 4 10
4 HMEC cells were added. The cells were allowed to
co-culture for 36h the cells were fixed and performed immunofluorescence for factor-VIII as described in the ‘Materials methods’ section and observed for
angiogenic response. Relative branch points and relative tube length were quantified as described in the ‘Materials and methods’ section. Columns, mean of
triplicate experiments; bars, s.e.; *Po0.01, significant difference from Daoy-P cells; **Po0.01, significant difference from Daoy-EV cells treated with SPARC
siRNA or anti-SPARC antibody (siRNA¼SPARC siRNA; anti-SP¼anti-SPARC antibody). (B) In vivo angiogenesis: Daoy-P, Daoy-EV and Daoy-SP cells
(1 10
6) were implanted into diffusion chambers and were surgically placed underneath the dorsal skin of athymic nude mice as described in the ‘Materials
and Methods’ section. PV, pre-existing vasculature; TN, tumour-induced vasculature. (C) Newly formed vessels were quantified and represented as per field.
Columns, mean of triplicate experiments; bars, s.e.; *Po0.01, significant difference from Daoy-EV cells. (D) Western blot analysis showing SPARC and
vascular endothelial growth factor (VEGF) levels with the treatment of siRNA against SPARC. GAPDH served as loading control.
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compared with controls (Figure 3D). The VEGFR2 and epidermal
growth factor receptor expression remained unchanged (Figures
3C and D).
Overexpression of SPARC inhibits MMP-9-mediated
angiogenesis activity and VEGF levels
The SPARC and MMP-9 are known to interact to regulate many
stages of tumour progression including ECM deposition, angio-
genesis and metastasis (Arnold et al, 2008). In addition, as
mentioned above, the RT
2 Profiler PCR Array for angiogenesis and
western blot analysis showed that SPARC overexpression led to
decreased expression of MMP-9 and VEGF (Figure 3B). We
therefore examined the possible role of MMP-9 in the anti-
angiogenic effect of SPARC-overexpressed Daoy medulloblastoma
cells. Our results show that MMP-9 activity and protein expression
were decreased in Daoy-SP2 cells, compared with Daoy-P and
Daoy-EV cells (Figure 4A). In addition, the expression of VEGF,
which has an essential role in endothelial proliferation and
angiogenesis, was also decreased in Daoy-SP2 cells compared with
parental and vector controls. We next examined the ability of
MMP-9 expression in Daoy-SP2 cells to induce angiogenesis in
vitro. Figure 4B indicates that ectopic expression of MMP-9 using a
vector expressing full-length MMP-9 cDNA in Daoy-SP2 cells
induced MMP-9 expression, which is comparable to that of
parental Daoy-P cells. Further, VEGF expression was also induced
in these cells, indicating that VEGF expression is dependent on
MMP-9 expression in SPARC-overexpressed cells (Figure 4A). To
elucidate the role of MMP-9 in SPARC-mediated inhibition of
tumour cell-induced angiogenesis, we performed real-time PCR
array for angiogenesis and western blot analysis with MMP-9
overexpression in Daoy-SP cells (Daoy-P vs Daoy-SP2þpcMMP9).
The results indicated that MMP-9 overexpression in Daoy-SP2
cells increased angiogenic factors and led to increased angio-
genesis. When adjusted for parental controls, densitometry analysis
indicated that VEGF, FGFR and PDGFR were increased by 60, 65
and 68%, respectively, in Daoy-SP2 cells treated with pcMMP-9
when compared with Daoy-SP2 cells. (Supplementary Figure 1).
To further characterise the role of MMP-9 in SPARC-mediated
inhibition of angiogenesis, we performed an in vitro angiogenic
assay with Daoy-SP2 cells transfected with MMP-9 cDNA. Figures
4B and C shows that ectopic expression of MMP-9 in Daoy-SP2
cells reversed the anti-angiogenic effects of these cells. We
exogenously added human recombinant SPARC protein and
determined weather Daoy tumour cells could induce tumour
cell-induced angiogenesis. Our data indicate that addition of
exogenous SPARC did not inhibit tumour cell-induced angio-
genesis, unlike the forced expression of SPARC (Figure 4E). In
addition, supplementing recombinant SPARC to Daoy-P cells,
comparable with that of the SPARC levels in DAOY-SP2 cells, did
not alter the angiogenic capability of these cells. Further addition
of recombinant SPARC did not change the expression of MMP-9
and VEGF, as observed in the case of SPARC-overexpressed
Dapy-SP2 cells (Figure 4D). These observations, taken together
with the studies presented in Figure 2, confirm that SPARC
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Figure 3 RT
2 profiler PCR array for angiogenic factors in secreted protein acidic and rich in cysteine (SPARC)-overexpressed Daoy cells. We used the
human angiogenesis signalling pathway RT
2 Profiler PCR Array to profile the expression of 84 genes related to the angiogenesis signalling pathway. (A) The
scatter plot of the test vs control samples indicates the validity of the experiment. (B) Graph showing decreased expression of several angiogenic factors and
increased expression of anti-angiogenic factors. (C) Daoy-P, Daoy-EV and Daoy-SP2 cell lysates were used to perform western blot analysis for the
angiogenic growth factors, i.e. vascular endothelial growth factor (VEGF), VEGFR2, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor
receptor (FGFR) and epidermal growth factor receptor (EGFR). GAPDH served as a loading control. (D) Protein levels were quantified by densitometry as
shown in the corresponding bar graph. All experiments were performed in triplicate with consistent results. Columns, mean of triplicate experiments; bars,
s.e.; *Po0.01, significant difference from Daoy-P cells.
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sexpression-mediated anti-angiogenic effects are due to
altered gene expression rather than due to the expression of
SPARC itself.
Overexpression of SPARC in medulloblastoma cells
inhibits tumourigenicity in nude mice
To assess the therapeutic efficacy of SPARC expression, Daoy-P,
Daoy-EV and Daoy-SP2 cells were injected intracranially into nude
mice. Mice injected with Daoy-P and Daoy-EV cells developed
tumours, became symptomatic within 6 weeks and were subse-
quently killed. In striking contrast, mice injected with Daoy-SP2
cells survived for 180 days, which was the designated end point of
the experiment. At this point, the animals were killed and their
brains were examined for tumour growth. Tumours volumes were
evaluated by measuring the maximum cross-sectional areas
stained for anti-human-specific MHC class-I IgG (western blot
analysis of MHC class-I IgG in tumours is shown (Supplementary
Figure 3) in digitalised sections of cerebellum/tumour.
Haematoxylin and eosin staining indicates significant tumour
growth in brains of mice implanted with Daoy-P and Daoy-EV
cells (Figure 5A). A corresponding statistically significant decrease
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endothelial growth factor (VEGF) protein levels. (A) Daoy-P, Daoy-EV and Daoy-SP2 cells were transiently transfected with a vector encoding full-length
MMP-9 cDNA (pcMMP-9). Gelatin zymography was carried out for MMP-9 activity. Western blot analysis was performed for MMP-9, SPARC and VEGF
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4 per well) were seeded in eight-well chamber slides transfected with pcMMP-9 and allowed to grow for 24h. Then, the medium was
removed and 4 10
4 HMEC cells were added. The cells were allowed to co-culture for 36h the cell are fixed and performed immunofluorescence
microscopy for factor-VIII as described in the ‘Materials and methods’ section and observed for angiogenic response. (C) Angiogenic result was quantified by
counting the relative branch points and tube length in five different fields from three independent experiments. Columns, mean of triplicate experiments; bars,
s.e.; *Po0.01, significant difference from Daoy parental cells; **Po0.01, significant difference from Daoy-SP cells without pcMMP-9 treatment.
(D) Parental Daoy cells were exogenously treated with recombinant human SPARC (rhuSPARC) for 36h. Gelatin zymography was carried out for MMP-9
activity. Western blot analysis was performed for SPARC and VEGF protein levels. The blots were stripped and reprobed with GAPDH antibody to detect
total amounts of the respective proteins. (E) Daoy-P, Daoy-EV and Daoy-SP2 cells (2 10
4 per well) were seeded in eight-well chamber slides and Daoy-P
cells were treated with rhuSPARC and allowed to grow for 24h and performed co-culture assay as described above. (F) Angiogenic result was quantified by
counting the relative branch points from three independent experiments. Columns, mean of triplicate experiments; bars, s.e. *Po0.01, significant difference
from Daoy-P cells.
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s(B65%) in mean tumour volume was found in animals
implanted with Daoy-SP2 (n¼6; mean tumour volume¼54000
pixels±7000) as compared with animals implanted with Daoy-EV
(n¼6; mean tumour volume¼156000 pixels±16000; Po0.001).
To determine whether SPARC was expressed in vivo, brain
sections were stained with a monoclonal antibody for human
SPARC. Figure 5A indicates that tumour sections from Daoy-SP2
tumours showed more staining than did Daoy-P and Daoy-EV
tumours. To assess whether MMP-9 inhibition mediated the
anti-tumour effects of SPARC expression, we analysed angiogenesis
in xenografts by histological analysis for CD-31, factor-VIII
and MMP-9 expression (Figure 5A). Estimation of CD-31 and
factor-VIII-positive areas in 20 randomly selected fields of
tumours from Daoy-EV and Daoy-SP provided some measure of
vascularity in the tumour sections (Figure 5C). Only a small
fraction (15–20%) of CD-31- or factor-VIII-positive areas
remained in Daoy-SP2 tumours in comparison with the controls.
It was also evident that the overexpression of SPARC in tumours
caused a decrease in MMP-9 expression in these tumours
(Figure 5A).
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consequences of SPARC expression on medulloblastoma tumour
formation in nude mice. Daoy-SP2 cells were transfected with
MMP-9 cDNA and were injected into the brains of nude mice, and
the formation of tumours was monitored. As shown in Figure 5A,
ectopic expression of MMP-9 using a vector expressing full-length
MMP-9 gene in Daoy-SP2 cells induced MMP-9 expression
comparable with that of parental Daoy-P cells. The MMP-9
induction reversed SPARC-mediated tumour growth inhibition
by 50%, with a mean tumour volume of 30% of the empty vector
control (Figure 5B). Accordingly, MMP-9, CD31 and factor-VIII
expression were increased in the tumour sections in these mice
compared with the tumour sections of mice with Daoy-SP2 cells
(Figure 5C). These results are consistent with a role for MMP-9 in
the SPARC-induced anti-angiogenic effect observed in vitro.
DISCUSSION
The SPARC is an ECM protein that influences the ‘soil’ in which
tumours develop. The ECM is known to influence tumour growth
directly (Netti et al, 2000; Hotary et al, 2003). The various activities
associated with SPARC are thought to facilitate different steps in
the formation of new vessels (Brekken and Sage, 2000). This study
reports that SPARC expression results in a significant decrease in
angiogenic capacities in vitro and in vivo and remarkably reduces
in vivo tumourigenicity of medulloblastoma cells.
The contradictory reports regarding the role of SPARC in cell
growth and tumour formation suggest that its effects are cell-type
specific and may be dependent on concentration and ECM
components. Therefore, the focus of this investigation was to
determine the role of SPARC in medulloblastoma (i.e., the
possibility of its use as a therapeutic target or agent). Using the
Daoy cell line stably transfected with SPARC cDNA, we determined
the contribution of SPARC in medulloblastoma tumour growth.
SPARC protein and gene transcript levels were increased by about
three-fold in Daoy-SP clones compared with Daoy-P and Daoy-EV
stable clones, as determined by western blotting and reverse
transcriptase PCR analyses. The SPARC expression inhibited
tumour cell-induced tube formation by endothelial cells in an in
vitro co-culture assay and abrogated induction of angiogenesis in a
dorsal window air sac assay in vivo. To investigate the function
of SPARC in the regulation of medulloblastoma tumour growth
in vivo, Daoy-SP cells were compared for their ability to form
tumours in an intracranial model. Overexpression of full-length
SPARC significantly reduced tumour size in xenografts. Therefore,
in medulloblastoma, SPARC expression is inversely correlated with
malignant phenotype. Previous studies have indicated that SPARC
contributes to the regulation of tumour formation, although its
role seems to be cell-type specific. The SPARC exerts growth
inhibitory activity on immortalised ovarian cancer cells in vitro
and in mouse xenograft explants (Abeysinghe et al, 2003).
Similarly, the tumour growth of glioma cells overexpressing
SPARC was delayed in vivo (Schultz et al, 2002). An inhibitory
effect of SPARC on proliferation and migration has been found in
breast and ovarian carcinoma cells (Dhanesuan et al, 2002).
Infection of MDA-231 breast carcinoma cells with osteonectin
decreased the in vitro invasion of these cells through Matrigel
(Koblinski et al, 2005). Overexpression of SPARC by ovarian
carcinoma cells led to increased tumour cell apoptosis, and the
levels of SPARC were inversely correlated with tumour progression
in vivo (Yiu et al, 2001). The growth of Lewis lung carcinoma and
B-cell lymphoma was enhanced in mice lacking endogenous
SPARC (Brekken et al, 2003). Pancreatic tumour growth was
enhanced in mice lacking endogenous SPARC (Puolakkainen et al,
2004).
Tumour growth has been shown to depend on angiogenesis.
Our study demonstrates that the anti-tumour effect of SPARC
expression in vivo is mediated, at least in part, by anti-vascular
effects. The reduced tumour growth in tumours formed with Daoy
cells expressing SPARC cDNA was associated with a decrease in
angiogenesis. Medulloblastomas produce a wide range of angio-
genic factors that are likely to have a direct role in tumour growth
(Pavlakovic et al, 2001a). Besides its effect on proliferation, SPARC
is thought to function in tissue remodelling and angiogenesis.
However, the role of SPARC on tumour cell-induced angiogenesis
has not been clearly established. Our results show that there was
reduced capillary tube formation when endothelial cells were
grown in the presence of Daoy-SP cells as compared with the
parental and vector controls in an in vitro angiogenic assay. In
addition to these in vitro anti-angiogenic activities, SPARC seems
to be anti-angiogenic in vivo, as demonstrated by the suppression
of neovascularisation in the dorsal window air sac assay. Analysis
of tumours formed with SPARC-overexpressing clones showed
that SPARC overexpression reduces vessel density as determined
by CD31 or factor-VIII staining. These results confirm that SPARC
is an inhibitor of tumour angiogenesis in vivo.
A variety of growth factors can stimulate angiogenesis. The most
important angiogenesis stimulators are VEGF (Veikkola and
Alitalo, 1999) and bFGF (Pavlakovic et al, 2001b). Tumour cells
may overexpress one or more of these angiogenic factors, which in
turn function synergistically to promote tumour growth. It has
been reported that some of the primitive neuroectodermal
tumours, which include medulloblastoma, show immunoreactivity
for VEGF and bFGF (Brem et al, 1992; Pietsch et al, 1997). In
another study, as determined by immunohistochemistry, VEGF
was expressed in all tested medulloblastoma tumours, suggesting
that inhibition of VEGF in medulloblastomas may result in the
inhibition of angiogenesis, as well as in tumour growth and
progression (Ozer et al, 2004). The relationship between SPARC
in tumour cells and the expression of angiogenic molecules, as
evaluated using a PCR array, indicated that several angiogenic
molecules were reduced in Daoy-SP cells compared with controls.
Similarly, results from the western blot analysis also showed the
downregulation of some potent angiogenic molecules, including
MMP-9, VEGF, PDGFR and FGF. These results suggest that SPARC
expression alters the angiogenic balance in the tumour micro-
environment by altering the expression of a complex array of
inhibitors and stimuli. Growth factors, such as VEGF or PDGF,
act directly on endothelial cells and/or activate inflammatory
cells (monocytes and T lymphocytes), which in turn synthesise
angiogenic factors. Previous studies demonstrated that SPARC
regulates additional components and coordinates the activity of
growth factors on endothelial cell proliferation and migration. The
SPARC antagonised the migratory response of endothelial cells
to bFGF without the binding of SPARC to bFGF or the blocking of
the ligand–receptor interaction (Hasselaar and Sage, 1992). The
SPARC modulates glioma growth by altering the tumour micro-
environment and suppressing tumour vascularity through sup-
pression of VEGF expression and secretion. (Yunker et al, 2008).
In this context, the suppression of angiogenesis-mediated tumour
growth by SPARC in medulloblastoma seems to be the conse-
quence of its ability to inhibit the expression of angiogenic factors
such as MMP-9, bFGF and VEGF in tumour tissues, which may in
turn inhibit capillary infiltration into tumours. We show that
MMP-9 expression in SPARC-overexpressed clones restored VEGF
expression and SPARC-induced anti-angiogenic effect. A positive
feedback regulation between MMP-9 and VEGF was reported in
retinal pigment epithelial cells (Hollborn et al, 2007). Our PCR
array analysis also indicates that MMP-9 induction induced HIF
expression (Supplementary Figure 1), a transcriptional factor for
VEGF (Hellwig-Burgel et al, 2005) that probably induced VEGF
levels.
Our results indicate that SPARC expression inhibits tumour
growth in vivo. We also show that this inhibition of tumour growth
could be mediated in part by inhibition of MMP-9. Our data also
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Daoy-SP2 cells, which show an increased anti-angiogenic effect
compared with other clones (Supplementary Figure 2). Our studies
indicate MMP-9 induction in Daoy-EV cell-induced angiogenesis,
as indicated by an increase in branch points and enhanced tumour
growth by 50% compared with that of controls. However, MMP-9
expression in Daoy-SP2 cells reversed the SPARC-mediated
inhibition of anti-angiogenic effect and tumour growth by only
about 50% compared with that of tumour cell-induced angiogenesis
and tumour growth in vivo induced by Daoy-SP2 cells, although
western blot analysis for MMP-9 indicated that transfection with
plasmid expressing MMP-9 cDNA in Daoy-SP2 cells restored the
expression of MMP-9 to that of parental cells (Figure 4A). In
addition, western blot analysis of VEGF expression indicated that
VEGF levels in MMP-9-induced Daoy-EV cells are almost two-fold
higher than that of parental control cells, which probably
contributed to the enhanced tumour growth induced by these
cells. However, VEGF expression in MMP-9-induced Daoy-SP cells
was restored to only about 70%. This suggests that factors other
than MMP-9 and VEGF are involved in SPARC-mediated
inhibition of tumour growth. Previous studies also indicate that
SPARC alters the expression of several genes involved in cell-cycle
progression, signalling and migration (Golembieski and Rempel,
2002). Moreover, we also show that SPARC inhibition with
SPARC siRNA or antibody in vitro did not reverse the effect of
SPARC-mediated inhibition of angiogenesis. In addition, exo-
genous addition of recombinant SPARC did not alter angiogenesis
or MMP-9 and VEGF levels (Figure 4D). These studies suggest that
decreased angiogenesis in SPARC-overexpressed cells could be due
to SPARC-induced altered cellular composition rather than the
effect of SPARC expression itself.
Little progress has been made in the development of molecular
targeted therapies for paediatric malignancies. This study provides
an insight into the possible functional roles of SPARC in
medulloblastoma tumour angiogenesis, and the data demonstrate
that SPARC expression is inversely correlated with medullo-
blastoma tumour growth in vivo.
ACKNOWLEDGEMENTS
We acknowledge Shellee Abraham for paper preparation, and
Sushma Jasti and Diana Meister for paper review. This research
was supported by National Cancer Institute Grant CA132853 (to
SL). The contents of this paper are solely the responsibility of the
authors and do not necessarily represent the official views of NIH.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, Keng P,
Wang N (2003) THY1 expression is associated with tumor suppression of
human ovarian cancer. Cancer Genet Cytogenet 143: 125–132
Arnold S, Mira E, Muneer S, Korpanty G, Beck AW, Holloway SE, Manes S,
Brekken RA (2008) Forced expression of MMP9 rescues the loss of
angiogenesis and abrogates metastasis of pancreatic tumors triggered by
the absence of host SPARC. Exp Biol Med (Maywood) 233: 860–873
Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N,
Varakis I (1997) Microvessel density in brain tumors. Anticancer Res 17:
4747–4753
Bellahcene A, Castronovo V (1995) Increased expression of osteonectin and
osteopontin, two bone matrix proteins, in human breast cancer. Am J
Pathol 146: 95–100
Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS (2008)
Blockade of tumor growth due to matrix metalloproteinase-9 inhibition
is mediated by sequential activation of beta1-integrin, ERK, and
NF-kappaB. J Biol Chem 283: 1545–1552
Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modu-
lators of cell function. Curr Opin Cell Biol 14: 608–616
Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that
functions in cellular differentiation and tissue response to injury. J Clin
Invest 107: 1049–1054
Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH
(2003) Enhanced growth of tumors in SPARC null mice is associated with
changes in the ECM. J Clin Invest 111: 487–495
Brekken RA, Sage EH (2000) SPARC, a matricellular protein: at the
crossroads of cell-matrix. Matrix Biol 19: 569–580
Brekken RA, Sage EH (2001) SPARC, a matricellular protein: at the
crossroads of cell-matrix communication. Matrix Biol 19: 816–827
Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF (1992)
Immunolocalization of basic fibroblast growth factor to the micro-
vasculature of human brain tumors. Cancer 70: 2673–2680
Chandrasekaran V, Ambati J, Ambati BK, Taylor EW (2007) Molecular
docking and analysis of interactions between vascular endothelial growth
factor (VEGF) and SPARC protein. J Mol Graph Model 26: 775–782
Chetty C, Bhoopathi P, Lakka SS, Rao JS (2007) MMP-2 siRNA induced
Fas/CD95-mediated extrinsic II apoptotic pathway in the A549
lung adenocarcinoma cell line. Oncogene 26: 7675–7683
Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, Rao JS (2008)
Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in
matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res 68:
4736–4745
Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A,
Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL (2002) SPARC is a key
Schwannian-derived inhibitor controlling neuroblastoma tumor angio-
genesis. Cancer Res 62: 7357–7363
Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P,
Cohn SL (2006) SPARC expression is associated with impaired tumor
growth, inhibited angiogenesis and changes in the extracellular matrix.
Int J Cancer 118: 310–316
Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW (2002)
Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in
MDA-MB-231 human breast cancer cells results in growth inhibition.
Breast Cancer Res Treat 75: 73–85
Ding Q, Grammer JR, Nelson MA, Guan JL, Stewart Jr JE, Gladson CL
(2005) p27Kip1 and cyclin D1 are necessary for focal adhesion kinase
regulation of cell cycle progression in glioblastoma cells propagated
in vitro and in vivo in the scid mouse brain. J Biol Chem 280: 6802–6815
Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK,
Friedman HS, Strother DR, Burger PC (2002) Histopathologic grading
of medulloblastomas: a Pediatric Oncology Group study. Cancer 94:
552–560
Framson PE, Sage EH (2004) SPARC and tumor growth: where the seed
meets the soil? J Cell Biochem 92: 679–690
Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH (1999)
SPARC regulates the expression of collagen type I and transforming
growth factor-beta1 in mesangial cells. J Biol Chem 274: 32145–32152
Francki A, Motamed K, McClure TD, Kaya M, Murri C, Blake DJ,
Carbon JG, Sage EH (2003) SPARC regulates cell cycle progression in
mesangial cells via its inhibition of IGF-dependent signaling. J Cell
Biochem 88: 802–811
Golembieski WA, Rempel SA (2002) cDNA array analysis of SPARC-
modulated changes in glioma gene expression. J Neurooncol 60: 213–226
Gondi CS, Lakka SS, Dinh D, Olivero W, Gujrati M, Rao JS (2004)
Downregulation of uPA, uPAR and MMP-9 using small, interfering,
hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and
tumor growth. Neuron Glia Biol 1: 165–176
Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP,
Schoenwaelder SM, Grotzer MA, Delattre O, Arcaro A (2008) Targeting
the PI3K p110alpha isoform inhibits medulloblastoma proliferation,
chemoresistance, and migration. Clin Cancer Res 14: 6761–6769
Hasselaar P, Sage EH (1992) SPARC antagonizes the effect of basic
fibroblast growth factor on the migration of bovine aortic endothelial
cells. J Cell Biochem 49: 272–283
SPARC inhibits tumour angiogenesis
P Bhoopathi et al
539
British Journal of Cancer (2010) 102(3), 530–540 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sHellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W (2005)
Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor
in immune reactions. J Interferon Cytokine Res 25: 297–310
Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L,
Bringmann A (2007) Positive feedback regulation between MMP-9 and
VEGF in human RPE cells. Invest Ophthalmol Vis Sci 48: 4360–4367
Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ (2003)
Membrane type I matrix metalloproteinase usurps tumor growth control
imposed by the three-dimensional extracellular matrix. Cell 114: 33–45
Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S,
Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK
(2005) Endogenous osteonectin/SPARC/BM-40 expression inhibits
MDA-MB-231 breast cancer cell metastasis. Cancer Res 65: 7370–7377
Kupprion C, Motamed K, Sage EH (1998) SPARC (BM-40, osteonectin)
inhibits the mitogenic effect of vascular endothelial growth factor on
microvascular endothelial cells. J Biol Chem 273: 29635–29640
Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao VH, Sioka C,
Rao JS (2005) Specific interference of uPAR and MMP-9 gene expression
induced by double-stranded RNA results in decreased invasion, tumor
growth and angiogenesis in gliomas. J Biol Chem 280: 21882–21892
Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST (2006) SPARC and Hevin
expression correlate with tumour angiogenesis in hepatocellular
carcinoma. J Pathol 210: 459–468
Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y,
Mordoh J, Podhajcer OL (1997) Suppression of SPARC expression by
antisense RNA abrogates the tumorigenicity of human melanoma cells.
Nat Med 3: 171–176
Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN,
Lakka SS, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Yung WK,
Rao JS (2001) Stable transfection of urokinase-type plasminogen
activator antisense construct modulates invasion of human glioblastoma
cells. Clin Cancer Res 7: 2519–2526
Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000) Role of
extracellular matrix assembly in interstitial transport in solid tumors.
Cancer Res 60: 2497–2503
Ozer E, Sarialioglu F, Cetingoz R, Yuceer N, Cakmakci H, Ozkal S, Olgun N,
Uysal K, Corapcioglu F, Canda S (2004) Prognostic significance of
anaplasia and angiogenesis in childhood medulloblastoma: a pediatric
oncology group study. Pathol Res Pract 200: 501–509
Packer RJ (1999) Childhood medulloblastoma: progress and future
challenges. Brain Dev 21: 75–81
Packer RJ, Vezina G (2008) Management of and prognosis with
medulloblastoma: therapy at a crossroads. Arch Neurol 65: 1419–1424
Pavlakovic H, Havers W, Schweigerer L (2001a) Multiple angiogenesis
stimulators in a single malignancy: implications for anti-angiogenic
tumour therapy. Angiogenesis 4: 259–262
Pavlakovic H, Von Schutz V, Rossler J, Koscielniak E, Havers W,
Schweigerer L (2001b) Quantification of angiogenesis stimulators in
children with solid malignancies. Int J Cancer 92: 756–760
Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK,
Wiestler OD (1997) Expression and distribution of vascular endothelial
growth factor protein in human brain tumors. Acta Neuropathol (Berl)
93: 109–117
Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P,
Chambon P, Gespach C (1995) Neoplastic progression of human
colorectal cancer is associated with overexpression of the stromelysin-3
and BM-40/SPARC genes. Int J Cancer 64: 70–75
Puolakkainen PA, Brekken RA, Muneer S, Sage EH (2004) Enhanced growth
of pancreatic tumors in SPARC-null mice is associated with decreased
deposition of extracellular matrix and reduced tumor cell apoptosis.
Mol Cancer Res 2: 215–224
Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH (1992) The
extracellular glycoprotein SPARC interacts with platelet-derived growth
factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its
receptors. Proc Natl Acad Sci USA 89: 1281–1285
Rao JS, Bhoopathi P, Chetty C, Gujrati M, Lakka SS (2007) Matrix
metalloproteinase-9 short interfering RNA induced senescence resulting
in inhibition of medulloblastoma growth via p16INK4 and mitogen-
activated protein kinase pathway. Cancer Res 67: 4956–4964
Rempel SA, Ge S, Gutierrez JA (1999) SPARC: a potential diagnostic marker
of invasive meningiomas. Clin Cancer Res 5: 237–241
Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM (2001)
Intellectual outcome after reduced-dose radiation therapy plus adjuvant
chemotherapy for medulloblastoma: a Children’s Cancer Group study.
J Clin Oncol 19: 3470–3476
Sage H, Johnson C, Bornstein P (1984) Characterization of a novel serum
albumin-binding glycoprotein secreted by endothelial cells in culture.
J Biol Chem 259: 3993–4007
Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA (2002) Secreted
protein acidic and rich in cysteine promotes glioma invasion and delays
tumor growth in vivo. Cancer Res 62: 6270–6277
Shankavaram UT, DeWitt DL, Funk SE, Sage EH, Wahl LM (1997)
Regulation of human monocyte matrix metalloproteinases by SPARC.
J Cell Physiol 173: 327–334
Veikkola T, Alitalo K (1999) VEGFs, receptors and angiogenesis.
Semin Cancer Biol 9: 211–220
Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison
NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC (1988)
UKCCCR guidelines for the welfare of animals in experimental neoplasia.
Lab Anim 22: 195–201
Yan Q, Sage EH (1999) SPARC, a matricellular glycoprotein with important
biological functions. J Histochem Cytochem 47: 1495–1506
Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC
(2001) SPARC (secreted protein acidic and rich in cysteine) induces
apoptosis in ovarian cancer cells. Am J Pathol 159: 609–622
Yunker CK, Golembieski W, Lemke N, Schultz CR, Cazacu S, Brodie C,
Rempel SA (2008) SPARC-induced increase in glioma matrix and
decrease in vascularity are associated with reduced VEGF expression and
secretion. Int J Cancer 122: 2735–2743
Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM,
Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR,
Guire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis
stage, adjuvant treatment, and residual tumor are prognostic
factors for medulloblastoma in children: conclusions from the
Children’s Cancer Group 921 randomized phase III study. J Clin Oncol
17: 832–845
SPARC inhibits tumour angiogenesis
P Bhoopathi et al
540
British Journal of Cancer (2010) 102(3), 530–540 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s